Pfizer's $1.72 Payout Eats 89% of Free Cash Flow as Bourla Takes the London Stage

Pfizer shareholders collecting $0.43 per share each quarter — $1.72 on an annualized basis — are being paid out of a cash stream that is shrinking faster than the dividend itself. Over the twelve months through June 28, the payout absorbed 89% of free cash flow, leaving precious little of that internally generated money for anything else. The strain was even more pronounced in fiscal 2025, when the dividend equaled 107.7% of free cash flow, meaning Pfizer handed back more than its operations produced after capital spending.

That arithmetic frames the challenge facing chief executive Albert Bourla, who is scheduled to appear at the Jefferies London Healthcare Conference on November 17, 2026, in a fireside chat starting at 9:00 GMT. The webcast is open to investors and the public, with registration details available from today. Bourla has insisted the company can sustain the dividend even under severely stressed scenarios — a pledge that holds only as long as Pfizer preserves the financial resilience underpinning it.

A growth engine running against a COVID undertow

The case for stability rests on Pfizer's newer franchises. Products launched or acquired in recent years lifted revenue 32% operationally in the third quarter of 2026, a group that includes Eliquis, Padcev, Vyndaqel, Nurtec and Lorbrena. Offsetting that momentum, COVID-related sales continue to fade: Paxlovid revenue fell 63% operationally in the quarter and Comirnaty slipped 29%.

Should investors sell immediately? Or is it worth buying Pfizer?

Those figures landed alongside a raised full-year outlook. On November 3, Pfizer reported third-quarter revenue of $16.6 billion and adjusted diluted earnings of $0.87 per share, then lifted its 2026 guidance to $62.0–64.0 billion in revenue and $2.95–3.05 in adjusted diluted EPS. The same day brought news that Cecile Guegan had been appointed chief financial officer and executive vice president, effective November 1.

Pipeline developments have added ballast. Pfizer disclosed roughly two weeks ago that the Phase 3 MagnetisMM-32 trial of ELREXFIO met its primary endpoint on progression-free survival versus investigator's choice of standard therapies in patients with relapsed or refractory multiple myeloma. On October 26, the FDA broadened approval of TALZENNA in combination with XTANDI to cover metastatic hormone-sensitive prostate cancer with HRR gene mutations. And on October 29, Edison Scientific announced an agreement to deploy its AI platform and Kosmos within Pfizer's biopharmaceutical research and development pipeline.

Patent cliffs loom over the payout math

Longer term, the dividend's durability hinges on whether new products can outrun expiring exclusivity. Analysts cited in media reports project revenue sliding to $55.4 billion by 2028, pointing to patent losses on Eliquis, Ibrance and Xtandi as the main drag. Management is countering with financial discipline and fresh productivity programs aimed at net cost savings, targeting risk-adjusted high single-digit annual revenue growth for 2028–2033. Guidance for 2027 is due at year-end.

For income investors, the calculus comes down to whether savings and new sales can widen the financial headroom enough for Pfizer to fund its payments increasingly from ongoing free cash flow — while still writing the checks for its pipeline and acquisitions, obesity among the priority investment areas. Bourla's remarks in London, and the 2027 forecast that follows, will be the next tests of that proposition.

Ad

Pfizer Stock: New Analysis - 11 November

Fresh Pfizer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Pfizer analysis...